Prepared as an outcome of ICMR Subcommittee on Non Hodgkin’s Lymphoma (High Grade) | This consensus document on management of non- hodgkin’s lymphoma – high grade summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molec...ular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
more
International Journal of Infectious Diseases 32 (2015) 111–117
PLOS ONE 10(12): e0144040. doi:10.1371/journal.pone.0144040
Manuel de mise en œuvre initiale
STAATSKOERANT, 5 MEI 2015 No. 38763
No. 38763 GOVERNMENT GAZETTE, 5 MAY 2015
General Notice
Notice 295 of 2015
Department of basic education
National education policy act, 1996 (Act No 27 of 1996)
Call for written submissions from stakeholder bodies and members of the public on Departmen...t of basic education draft national policy on HIV, STIs and TB
more
Djibuti et al. BMC Public Health (2015) 15:427 DOI 10.1186/s12889-015-1760-z
This strategy has been developed with a view to managing climate-induced internal displacement (CIID) in a comprehensive and rights-based manner. It is part of the action plan for the Government of Bangladesh (GoB) to implement the Sendai Framework.
The strategy focuses solely on internal disp...lacements caused by climate-related disasters and not cross-border displacement issues. It aims to chalk out a comprehensive strategy covering all three phases of displacements: (i) pre-displacement; (ii) displacement phase; and (iii) post-displacement. The multidimensional characteristics of the Strategy require participation of all relevant ministries with a target to integrate the concerns of CIIDPs into the existing programmes of all these ministries.
more
ECDC Technical Report
In line with ECDC’s recommendations provided in the ’Risk Assessment of HTLV-1/2 transmission by tissue/cell transplantation’ dated 14 March 2012, this Directive replaces the term ‘incidence’ with ‘prevalence’ in the description of endemic areas of HTLV-1/2 i...nfection. According to the new requirements ‘HTLV-1 antibody testing must be performed for donors living in, or originating from high-prevalence areas or with sexual partners originating from those areas or where the donor’s parents originate from those areas’ and this applies to both donors of non-reproductive tissues and cells and reproductive cells.
ECDC contracted experts from the Institut Pasteur in Paris to systematically review the published evidence on the distribution of HTLV-1 infection prevalence throughout the world and to identify high-prevalence countries and areas.
more
Rwanda Guidelines for variation to registered pharmaceutical products.